Insider Cluster (2 insiders) ·Filed Aug 7, 2026

INCY

INCYTE CORP
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $2.2M total
Actionable Insight • Neutral

The insider selling is immaterial and likely post-earnings routine activity. Monitor for any larger open-market sales by C-suite executives, but this cluster alone warrants no trading action.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
INCY ▲ +2.34% at T+20d
NEUTRAL call ✓ call won +2.34% · α vs SPY +3.26% · entry $121.55 → $124.40
Next anchor: T+60d in 4w
Latest observation: T+36 +0.44% FF3 residual α
Entry anchored
Aug 7, 03:59 PM ET
via exact tick
T+1d
-0.39%
call -0.39% · α -0.08%
$121.07
settled 8w ago
T+5d
+1.60%
call +1.60% · α +1.65%
$123.50
settled 7w ago
T+20d
+2.34%
call +2.34% · α +3.26%
$124.40
settled 28d ago
T+60d
—
call — · α —
—
in 4w

Price Chart

Loading chart...

Executive Summary

Two senior R&D executives at Incyte (President and Chief Scientific Officer) sold a combined $2.18M of stock in the week following the Q2 earnings beat. The sales are trivial relative to Incyte's $24B market cap (0.009%) and likely reflect routine post-earnings window rebalancing and derivative exercise coverage, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$2.2M
Insiders
2

Key Facts

  • Pablo J. Cagnoni (President, Global Head of R&D) sold $1.90M on 2026-07-31; Patrick A. Mayes (EVP & Chief Scientific Officer) sold ~$274K on 2026-08-05 after exercising options
  • Total cluster value: $2.18M (0.009% of $24B market cap)
  • Cluster occurred 3–10 days after Incyte's Q2 2026 earnings (8-K filed 7/28), which beat consensus but included a one-time CMS settlement benefit
  • Mayes' sales corresponded with derivative exercises at $105–$106 strike, suggesting tax- or exercise-cost coverage

Financial Impact

Trivial insider selling — $2.18M total vs $24B market cap (0.009%). No material impact.

insider holdings

Risk Factors

  • Larger insider sales in coming weeks could shift sentiment
  • Q2 earnings beat was partly one-time; future quarters may not sustain the same earnings power

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
52% bullish (33 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-INCY-1786132957799
9 reports for INCY
Performance horizon
33% Hit rate 1 of 3 directional calls best @ T+60▲ +23.70%Jun 8, 2026
Filters
Rows
Reports for INCY — sortable, filterable
TypeNow
Aug 14, 2026
7w ago
Insider Cluster
BEARISH ★ 4/10
$120.16 $122.19▼ −1.69%▼ −3.68%$115.30 (+4.04%)
Aug 7, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$121.55 $124.40▲ +2.34%▲ +3.26%$115.30 (−5.14%)
Aug 4, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$120.60 $124.50▲ +3.23%▲ +4.47%$115.30 (−4.39%)
Jul 28, 2026
9w ago
8-K
MIXED ★ 6/10
$129.93 $129.72▼ −0.16%▼ −3.54%$115.30 (−11.26%)
Jul 20, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$115.65 $123.50▲ +6.79%▲ +2.67%$115.30 (−0.30%)
Jul 20, 2026
10w ago
Insider Cluster
NEUTRAL ★ 2/10
$115.65 $123.50▲ +6.79%▲ +2.67%$115.30 (−0.30%)
Jun 8, 2026
16w ago
8-K
BULLISH ★ 7/10
$100.64 $115.62▲ +14.88%▲ +13.25%$115.30 (+14.57%)
May 27, 2026
18w ago
DEFA14A
NEUTRAL ★ 3/10
$97.26 $108.46▲ +11.52%▲ +13.82%$115.30 (+18.55%)
Feb 28, 2026
30w ago
Institutional Cluster
BULLISH ★ 6/10
$99.73 $90.31▼ −9.45%▼ −1.51%$115.30 (+15.62%)
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (65h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 7, 2026